(Q30885947)

English

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Alessandra Ferrajoli

9

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

7

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Srdan Verstovsek

10

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

William G Wierda

11

object named as

William Wierda

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Jorge Eduardo Cortes

3

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

2

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

5

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Guillermo Garcia-Manero

8

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Michael J. Keating

12

object named as

Michael Keating

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Francis J Giles

4

object named as

Francis J Giles

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

6

object named as

Jianqin Shan

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

13

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

2636-2642

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonmalignant late effects after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11831

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11831

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30885947&oldid=2049908472"